In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

University of Pittsburgh Medical Center (UPMC)

https://www.upmc.com/

Latest From University of Pittsburgh Medical Center (UPMC)

ESMO: Cardiff Oncology Falls Despite Onvansertib’s Broad Potential In KRAS-Mutant CRC

A planned Phase II trial for PLK1 inhibitor onvansertib in KRAS-mutant colorectal cancer may support accelerated approval, but results are two years off and the company cut its prostate cancer plans to conserve cash.

Clinical Trials Personalized Medicine
See All

Company Information

  • Industry
  • Academic and Research Institutions
  • Other Names / Subsidiaries
    • University of Pittsburgh Medical Center (UPMC) Enterprises
UsernamePublicRestriction

Register